# US 8,277,845 B2 · Formulations and methods for lyophilization and lyophilates provided thereby

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,845 B2
- Document ID: US8277845B2
- Status: Granted
- Kind: B2
- Application number: 12/746,164
- Filed: 2008-12-03
- Published: 2010-10-28
- Granted: 2012-10-02
- Earliest claimed: 2007-12-04
- Assignees: Remedy Pharmaceuticals, Inc.
- Inventors: Sven Jacobson
- Web page: https://patentgrep.com/patent/US8277845B2

## CPC

- A61K 9/1682: {Processes}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/1611: {Inorganic compounds}
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 31/175: having the group [IMAGE cpc-sch-A61K-0950.gif] , >N—C(O)—N=N— or[IMAGE cpc-sch-A61K-0951.gif] , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
- A61K 31/451: having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A61K 31/64: Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 31/04: Antibacterial agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compositions, methods for lyophilizing compounds and making pharmaceutical compositions, and kits providing solutions and lyophilized formulations of compounds. The compositions, methods, and kits are particularly useful in pharmaceutical applications involving therapeutic agents that have low solubility at low pH and medium pH values. Certain embodiments provide methods for lyophilizing compounds in liquid solutions, which include the steps of: a) preparing aqueous solutions of a compound of interest in the absence of buffer; b) adjusting the pH to high values of pH in order to increase the solubility of the compound of interest; and c) freeze-drying the solution to provide a lyophilized solid composition. Aqueous solutions including buffer are also disclosed. Lyophilized formulations, including micronized and non-micronized powders, are provided.

## Claims

### Claim 1

A solid pharmaceutical composition comprising a lyophilized glibenclamide powder substantially free of buffer, including one or more substantially pharmaceutically inert compounds and one or more alkali bases, and being substantially free of other agents that enhance the solubility of glibenclamide, wherein said lyophilized glibenclamide powder comprises less than about 1% w/w buffer and the weight of substantially pharmaceutically inert compounds comprises at least about 10 times the weight of glibenclamide in the solid pharmaceutical composition.

### Claim 2 (depends on 1)

The solid pharmaceutical composition of claim 1, wherein the one or more substantially pharmaceutically inert compounds are independently selected from a sugar and a salt.

### Claim 3 (depends on 1)

The solid pharmaceutical composition of claim 1, wherein the substantially pharmaceutically inert compounds are independently selected from glucose, fructose, mannose, galactose, mannitol, sorbitol, lactose, trehalose, sucrose, sodium chloride, and potassium chloride.

### Claim 4 (depends on 1)

The solid pharmaceutical composition of claim 1, wherein the alkali base is sodium hydroxide or potassium hydroxide.

### Claim 5 (depends on 1)

The solid pharmaceutical composition of claim 1, wherein one of the substantially pharmaceutically inert compounds is mannitol and the alkali base is sodium hydroxide.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The solid pharmaceutical composition of any one of claims 1-5, wherein the amount of buffer comprises less than about 0.1% w/w.

### Claim 7 (depends on 1)

The solid pharmaceutical composition of claim 1, wherein the weight of substantially pharmaceutically inert compounds comprises at least about 30 times the weight of glibenclamide in the solid pharmaceutical composition.

### Claim 8 (depends on 1)

The solid pharmaceutical composition of claim 1, wherein said pharmaceutically inert compound is a bulking agent is selected from the group consisting of a mono-saccharide and di-saccharide.

### Claim 9 (depends on 1)

The solid pharmaceutical composition of claim 1, wherein the weight of substantially pharmaceutically inert compounds comprises at least about 100 times the weight of glibenclamide in the solid pharmaceutical composition.
